Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine in ALS
NCT00409721Phase 2Completed
- Sponsor
- University of Alberta
- Start
- Mar 2007
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of memantine in amyotrophic lateral sclerosis (ALS), sponsored by University of Alberta. Primary endpoints: ALS Functional Rating Scale-Revised, Forced Vital Capacity and 1 more. Started Mar 2007; status: completed.
02
Drugs
memantine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00409721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00409721.